Aranesp Solution
Product Images NDC 55513-003

Product Visual Gallery

This gallery contains 43 technical images submitted to the FDA as part of the official labeling for Aranesp (NDC 55513-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Aranesp 03)

An instructional illustration showing components for injection preparation: a vial, a disposable syringe with needle cover and plunger rod, alcohol wipes, a cotton ball, and a puncture-proof container labeled with a biohazard symbol.*

FDA Label Image

Figure 2 (Aranesp 04)

An instructional illustration labeled 'Figure 2' showing a pair of hands being washed under running water from a faucet, with water droplets depicted falling from the hands.*

FDA Label Image

Figure 3 And 4 (Aranesp 05)

Illustration showing two steps of handling a vial: Figure 3 depicts a hand grasping a vial, and Figure 4 shows a hand removing the vial's cap or cover. This instructional diagram relates to preparation or administration processes for the ARANESP solution.*

FDA Label Image

Figure 5 And 6 (Aranesp 06)

Illustrative instructional diagram showing how to remove the cap from a syringe by pulling straight off (Figure 5) and how to prepare the syringe for use by holding it correctly with both hands (Figure 6). The drawings depict proper handling techniques for the syringe associated with ARANESP (darbepoetin alfa) administration.*

FDA Label Image

Figure 7 (Aranesp 07)

An instructional line drawing labeled Figure 7 illustrating a hand inserting a syringe needle into a vial. The image demonstrates the proper technique for drawing medication from the vial using the syringe.*

FDA Label Image

Figure 8 (Aranesp 08)

A black and white instructional illustration showing two hands holding a vial and a syringe. One hand holds the vial inverted, while the other hand holds a syringe with the needle inserted into the vial, drawing liquid. The figure is labeled as 'Figure 8.' This likely demonstrates the process of withdrawing medication.*

FDA Label Image

Figure 9 And 10 (Aranesp 09)

Illustrations showing two steps of syringe plunger manipulation. Figure 9 depicts a hand holding a syringe with the plunger pushed upward, while Figure 10 shows the plunger being pushed downward by the thumb. Both figures focus on correct handling technique for the syringe needle and plunger.*

FDA Label Image

Figure 11 (Aranesp 0a)

Illustration showing recommended injection sites for ARANESP solution. Front view highlights the abdomen and the front thigh areas as injection sites, and the back view highlights the upper buttocks area. These sites indicate locations for subcutaneous or intravenous administration.*

FDA Label Image

Figure 12 (Aranesp 0b)

An instructional line drawing showing the proper injection site on the outer thigh for subcutaneous administration, depicting a hand holding the injection device against the skin. Labeled as Figure 12.*

FDA Label Image

Figure 13 (Aranesp 0c)

An instructional illustration labeled 'Figure 13' shows a person seated with one hand placed on the upper thigh. The image likely demonstrates a step or position related to the administration of an injectable medication.*

FDA Label Image

Figure 14 (Aranesp 0d)

An instructional illustration labeled Figure 14 showing a hand positioning for injection at angles of 0°, 45°, and 90° relative to the skin, with the skin indicated on the upper leg area, demonstrating proper injection angles.*

FDA Label Image

Figure 15 (Aranesp 0e)

An instructional illustration labeled 'Figure 15' showing a hand operating an intravenous or infusion line component, likely demonstrating how to manipulate or adjust part of the infusion device used with ARANESP (darbepoetin alfa) solution for intravenous or subcutaneous administration.*

FDA Label Image

16 (Aranesp 0f)

An instructional illustration labeled Figure 16, showing a syringe needle inserting into the top of an inline medical device connected to tubing on both ends. The image demonstrates a step in administering or preparing an intravenous infusion setup.*

FDA Label Image

Before Use And After Use (Aranesp 11)

An instructional diagram showing a syringe before and after use. The syringe parts are labeled, including plunger rod, finger grip, label and expiration date, yellow safety guard, syringe barrel, medicine window with markings, and gray needle cap. The after-use syringe shows the used plunger rod, extended yellow safety guard, and gray needle cap removed.*

FDA Label Image

Open The Package And Remove The Syringe From The Tray. Grab The Yellow Safety Guard To Remove The Prefilled Syringe From The Tray. (Aranesp 12)

Instructional illustration showing how to handle the ARANESP prefilled syringe by grabbing the yellow safety guard, as indicated by red arrows and accompanying text. The image demonstrates safe syringe usage technique for darbepoetin alfa solution administration.*

FDA Label Image

B Inspect The Medicine And Prefilled Syringe. (Aranesp 13)

An illustration showing a prefilled syringe of ARANESP (darbepoetin alfa) solution with a gray needle cap. Labels indicate the location of the label and expiration date on the syringe barrel, and a medicine window with markings showing the visible medication volume inside the syringe.*

FDA Label Image

C Gather All Materials Needed For Your Injection. (Aranesp 14)

An illustration showing a prefilled syringe with a yellow solution, three round white tablets, an adhesive bandage strip, a small wipe packet, and a red biohazard sharps container. This setup suggests components related to administering an injectable medication and related supplies for injection and post-injection care.*

FDA Label Image

D Prepare And Clean Your Injection Site(s). (Aranesp 15)

An illustration diagram showing recommended injection sites on the human body for subcutaneous administration. The labeled areas include the upper arm, stomach area (abdomen), thigh, and buttocks from front and back views of a human figure.*

FDA Label Image

Hold The Prefilled Syringe By The Syringe Barrel. Carefully Pull The Gray Needle Cap Straight Off And Away From Your Body. (Aranesp 16)

An instructional illustration showing hands removing the syringe barrel cap from a prefilled syringe. A smaller inset depicts disposal of the syringe cap into a biohazard sharps container, indicating safe handling during preparation for injection.*

FDA Label Image

Check Your Prescription Before You Inject Your Dose. (Aranesp 17)

A warning panel featuring a red octagonal stop sign icon followed by red text advising to check the prescription before injecting the dose. This is a medication use caution related to the correct dosing of the drug.*

FDA Label Image

G Point The Needle Up And Tap Gently Until The Air Rises To The Top. (Aranesp 18)

An instructional illustration showing hands holding a syringe with a yellow-capped vial or cartridge attached, demonstrating the preparation or handling of an injectable solution dose. The image portrays the steps for using a prefilled injection device for subcutaneous or intravenous administration.*

FDA Label Image

H Slowly Push The Plunger Rod Up To The Line On The Syringe Barrel That Matches Your Prescribed Dose. (Aranesp 19)

Instructional illustration showing hands holding a syringe with the plunger being pulled up, depicting how to adjust the plunger to the prescribed dose for injection. A close-up view highlights the plunger inside the syringe barrel with a label indicating the prescribed dose position.*

FDA Label Image

I Pinch Your Injection Site To Create A Firm Surface. (Aranesp 1a)

An instructional illustration showing a person pinching their abdominal skin with one hand and holding a syringe at a 90-degree angle above the pinched site, indicating how to administer a subcutaneous injection into the abdomen.*

FDA Label Image

J Hold The Pinch. Insert The Needle Into The Skin At 45 To 90 Degrees. (Aranesp 1b)

An instructional diagram illustrating the technique for subcutaneous injection, showing a hand holding a syringe inserted into a finger-pinch of skin at a 45-degree angle. A smaller box indicates a 90-degree angle for comparison.*

FDA Label Image

When Done, Gently Pull The Syringe Off Of Your Skin, And Continue To Step 4: Finish. (Aranesp 1c)

An instructional illustration showing a hand holding a syringe and administering an injection subcutaneously into the abdominal area. The image demonstrates the proper technique for using the ARANESP prefilled syringe for subcutaneous injection.*

FDA Label Image

Or (Aranesp 1d)

FDA Label Image

Before You Finish (Aranesp 1e)

FDA Label Image

For Your Safety, Pull The Yellow Safety Guard Until It Clicks And Covers The Needle. (Aranesp 1f)

An instructional illustration showing a hand holding a syringe with a yellow cap. The image highlights the part of the syringe to grab with a red arrow labeled "GRAB HERE," and an upward black arrow indicates pulling the yellow cap off the syringe.*

FDA Label Image

M Discard (throw Away) The Used Prefilled Syringe. (Aranesp 20)

An instructional illustration showing a hand placing a yellow capped syringe or vial into a red biohazard sharps disposal container with a flap lid. The biohazard symbol is visible on the front of the container.*

FDA Label Image

Principal Display Panel (10 mcg/0.4 mL Syringe Blister Pack Package)

Packaging label for Aranesp (darbepoetin alfa) single-dose prefilled syringes, 10 mcg/0.4 mL solution for intravenous or subcutaneous use. The yellow label shows the Amgen logo, dosage strength, usage instructions, storage conditions, and that the product is albumin-free and preservative-free. It includes 4 prefilled syringes with 27 gauge needles.*

FDA Label Image

Principal Display Panel (25 mcg/0.42 mL Syringe Blister Pack Package)

Label for ARANESP (darbepoetin alfa) solution, single-dose vial with strength 300 mcg/mL. The label states the product is albumin free and includes storage instructions (2° to 8°C), no freezing, and protection from light. It also notes the drug is for intravenous or subcutaneous use and is sterile, with no preservative. Manufactured by Amgen, Inc.*

FDA Label Image

Principal Display Panel (40 mcg/0.4 mL Syringe Blister Pack Package)

The image shows the carton label for Aranesp SingleJect 40 mcg/0.4 mL prefilled syringes. The product contains darbepoetin alfa recombinant solution, albumin-free, intended for intravenous or subcutaneous use. The carton contains 4 syringes of 40 mcg/0.4 mL each. Manufactured by Amgen Inc, the label includes storage instructions, a warning to avoid reuse, and a note about dry natural rubber content.*

FDA Label Image

Principal Display Panel (60 mcg/0.3 mL Syringe Blister Pack Package)

Aranesp (darbepoetin alfa) SingleJect single-dose prefilled syringes, 60 mcg/0.3 mL sterile solution for intravenous or subcutaneous use. The yellow carton shows that it contains 4 syringes of 60 mcg/0.3 mL each, is albumin free, and includes 27 gauge needles. Manufactured by Amgen, Inc.*

FDA Label Image

Principal Display Panel (100 mcg/0.5 mL Syringe Blister Pack Package)

Aranesp SingleJect (darbepoetin alfa) recombinant sterile solution, 100 mcg/0.5 mL, single-dose prefilled syringes with 27 gauge needles. The yellow label indicates albumin-free solution for intravenous or subcutaneous use, with storage instructions and warnings including no preservatives and single-use only. Manufactured by Amgen Inc.*

FDA Label Image

Principal Display Panel (150 mcg/0.3 mL Syringe Blister Pack Package)

Aranesp SingleJect 150 mcg/0.3 mL prefilled syringes by Amgen, Inc. The yellow carton contains four single-dose prefilled syringes with 27 gauge needles. The label indicates the product is darbepoetin alfa recombinant, albumin-free, sterile solution for intravenous or subcutaneous use, and includes storage and handling instructions.*

FDA Label Image

Principal Display Panel (200 mcg/0.4 mL Syringe Blister Pack Package)

Packaging label for Aranesp SingleJect (darbepoetin alfa) recombinant solution, 150 mcg/0.3 mL prefilled syringes. The label indicates it is for intravenous or subcutaneous use, albumin free, with no preservative. The product is supplied by Amgen, Inc and contains 4 single-dose prefilled syringes with 27 gauge needles. Storage instructions and the presence of natural rubber are also noted.*

FDA Label Image

Principal Display Panel (300 mcg/0.6 mL Syringe Blister Pack Package)

Aranesp 200 mcg/0.4 mL solution single-dose prefilled syringe label by Amgen, Inc. The label shows the product name, dosage strength, route as intravenous or subcutaneous, and storage instructions including temperature and light protection. It also highlights that the product is albumin free and contains dry natural rubber.*

FDA Label Image

Principal Display Panel (500 mcg/1 mL Syringe Blister Pack Package)

ARANESP SingleJect 300 mcg/0.6 mL solution in a single-dose prefilled syringe with a 27 gauge needle. The label states the product is recombinant darbepoetin alfa, albumin free, and manufactured by Amgen, Inc. Storage instructions indicate 2°C to 8°C, avoid freezing and light exposure. The package contains one syringe.*

FDA Label Image

Principal Display Panel (25 mcg/1 mL Vial Package)

Label for Aranesp SingleJect (darbepoetin alfa) 25 mcg/0.42 mL solution for intravenous or subcutaneous use by Amgen, Inc. The sterile, preservative-free single-dose prefilled syringe contains 25 mcg with albumin-free formulation. Storage instructions specify 2° to 8°C, with protection from freezing, shaking, and light. Contains dry natural rubber components.*

FDA Label Image

Principal Display Panel (40 mcg/1 mL Vial Package)

ARANESP SingleJect 40 mcg/0.4 mL prefilled syringes by Amgen, Inc. The label indicates the product is a sterile solution for intravenous or subcutaneous use only. It contains recombinant darbepoetin alfa, is albumin-free, and contains dry natural rubber. The package includes four 40 mcg/0.4 mL syringes with 27 gauge needles. Storage instructions specify 2° to 8°C, with protection from freezing and light.*

FDA Label Image

Principal Display Panel (60 mcg/1 mL Vial Package)

Aranesp (darbepoetin alfa) SingleJect 60 mcg/0.3 mL solution, a single-dose prefilled syringe for intravenous or subcutaneous use. The label indicates it is sterile, albumin-free, and contains no preservative. Packaged by Amgen, Inc., the product requires storage at 2° to 8°C and protection from freezing, shaking, and light.*

FDA Label Image

Principal Display Panel (100 mcg/1 mL Vial Package)

Aranesp (darbepoetin alfa) SingleJect 100 mcg/0.5 mL solution for intravenous or subcutaneous use. The label indicates a sterile, preservative-free formulation that is albumin free, with storage instructions to keep refrigerated at 2° to 8°C, avoiding freezing, shaking, and light exposure. The package contains 4 single-dose prefilled syringes with 27 gauge needles, labeled by Amgen, Inc.*

FDA Label Image

Principal Display Panel (200 mcg/1 mL Vial Package)

Aranesp (darbepoetin alfa) SingleJect 10 mcg/0.4 mL solution in a single-dose prefilled syringe with 27 gauge needles, by Amgen. The label states it is albumin free, for intravenous or subcutaneous use, sterile with no preservative, and contains dry natural rubber. Storage instructions and manufacturer information are shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.